Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Aziende Chimiche Riunite Angelini Francesco clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our Italy and Poland registers with Aziende Chimiche Riunite Angelini Francesco as lead sponsor. Synced 16 Nov 2026
3Current trials
1Recruiting now
0Drugs in these trials
2Trial registers
At a glance

Aziende Chimiche Riunite Angelini Francesco is the lead sponsor of 3 current clinical trials in our Italy and Poland registers. 1 is recruiting patients now. All registered phases are Observational. The most-studied condition is Epilepsy.

ClinicalTrials.gov trials by status

  • Recruiting133%
  • Active, closed267%

Trials by phase

  • Observational3100%
01

Clinical trials sponsored by Aziende Chimiche Riunite Angelini Francesco

3 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Real-world Clinical Response to Trazodone in Italy, Poland, and Romania
NCT07377682 · Depression - Major Depressive Disorder, Cognition Disorders in Old Age
Observational Recruiting 2025-12 Poland
Cenobamate in Adults With Focal-Onset Seizures
NCT05859854 · ClinicalTrials.gov ↗ · Epilepsy, Focal-Onset Seizure, Neurological Disorder
Observational Active, closed 2023-01 Italy
Adjunctive Anti-seizure Medication (ASM) Real World Evidence (RWE) Study
NCT05867160 · ClinicalTrials.gov ↗ · Epilepsy
Observational Active, closed 2023-05 Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Aziende Chimiche Riunite Angelini Francesco trials

5 conditions
Epilepsy2Focal-Onset Seizure1Neurological Disorder1Depression - Major Depressive Disorder1Cognition Disorders in Old Age1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in Italy20
Clinical trials in Poland11

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Epilepsy

SponsorTrials
Hospices Civils de Lyon10
Fondation Ophtalmologique Adolphe de Rothschild6
Rapport Therapeutics4
University Hospital, Toulouse4
Assistance Publique Hopitaux De Marseille3
IRCCS National Neurological Institute "C. Mondino" Foundation3
IRCCS Eugenio Medea3
NaviFUS Corporation2
Shen Chun-Hong2
Shanghai UniXell Biotechnology1

Sponsors with the most current trials registered for this condition.

05

Questions about Aziende Chimiche Riunite Angelini Francesco trials

How many clinical trials does Aziende Chimiche Riunite Angelini Francesco sponsor?

Aziende Chimiche Riunite Angelini Francesco is the lead sponsor of 3 current trials on ClinicalTrials.gov in our Italy and Poland registers, as of the registry sync on 16 November 2026. Completed and withdrawn studies are not counted.

Are Aziende Chimiche Riunite Angelini Francesco trials recruiting?

Yes. 1 of its 3 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.